Clomid and Tadalafil Interaction: What Women Need to Know

What Is This Drug Combination and Why Does It Come Up?

Clomiphene citrate and tadalafil are rarely prescribed together in women, but the combination surfaces in two specific clinical situations. First, women with pulmonary arterial hypertension (PAH) who are also being evaluated for infertility may be offered Clomid for ovulation induction while already taking tadalafil for their cardiac condition. Second, a body of early research has explored whether tadalafil, a phosphodiesterase type 5 inhibitor (PDE5i), might improve endometrial receptivity or uterine blood flow in women undergoing ovulation induction.

Understanding the interaction requires looking at each drug's mechanism, their metabolic pathways, and the indirect risks that arise when you combine a vasodilator with a drug that alters the hypothalamic-pituitary-ovarian (HPO) axis.

How Clomiphene Works in Women

Clomiphene is a selective estrogen receptor modulator (SERM). It binds estrogen receptors in the hypothalamus, blocks negative feedback, and drives a compensatory surge of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) according to the FDA-approved prescribing information for clomiphene citrate. The standard starting dose is 50 mg orally once daily for 5 days, beginning on cycle day 3, 4, or 5.

Clomiphene is metabolized in the liver. Its primary metabolite, enclomiphene, has a half-life of approximately 5 to 7 days, while the zuclomiphene isomer can persist in tissue for weeks. Both isomers are substrates of cytochrome P450 3A4 (CYP3A4) and to a lesser extent CYP2D6, though clomiphene is not a potent inhibitor or inducer of either enzyme at therapeutic doses.

How Tadalafil Works

Tadalafil inhibits PDE5, the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in smooth muscle. The result is vasodilation, both systemically and in target tissues such as pulmonary vasculature, penile tissue (in men), and potentially uterine and ovarian vasculature. In women, tadalafil is FDA-approved at 40 mg once daily for PAH under the brand name Adcirca, and at lower doses for erectile dysfunction in male patients under Cialis. Off-label gynecologic use in women is investigational.

Tadalafil is also a CYP3A4 substrate. It is not a clinically significant inhibitor of CYP3A4 at approved doses.

The Pharmacokinetic Interaction: Is There One?

The short answer is no, there is no direct clinically significant pharmacokinetic interaction between clomiphene and tadalafil. Because both drugs rely on CYP3A4 for hepatic metabolism, there is a theoretical potential for competition at that enzyme, but neither drug inhibits CYP3A4 strongly enough at standard doses to alter the other's plasma concentration in a clinically meaningful way.

What the Interaction Databases Say

Standard drug interaction databases, including Lexicomp and Micromedex, do not classify a clomiphene-tadalafil pairing as a contraindicated or major interaction. The absence of a direct DDI flag means there is no dose adjustment required for either drug based on co-administration alone.

Where risk does exist is pharmacodynamic, not pharmacokinetic.

The Pharmacodynamic Risk: Blood Pressure

Tadalafil causes dose-dependent systemic vasodilation. If you are also taking organic nitrates (such as nitroglycerin or isosorbide mononitrate) for cardiac conditions, combining them with tadalafil creates a risk of severe, potentially life-threatening hypotension. The FDA label for tadalafil carries a contraindication for concurrent use with any form of organic nitrate. This contraindication applies regardless of whether Clomid is in the picture, but it is a critical safety check in any woman being managed for PAH who is also receiving fertility treatment.

Clomiphene itself does not cause hypotension. It does not interact with the nitrate pathway. So the blood-pressure risk is tadalafil-specific, not a product of the Clomid-tadalafil combination per se.

Tadalafil and Uterine Blood Flow: The Research Field for Women

This is where the combination becomes genuinely interesting from a women's-health standpoint, and where the evidence is thin enough to warrant candor.

A small number of investigators have proposed that PDE5 inhibitors, including sildenafil and tadalafil, might improve endometrial thickness and uterine artery blood flow in women undergoing ovulation induction or IVF. The rationale is that cGMP-mediated vasodilation in the uterine and spiral arteries could create a more receptive endometrial environment.

What the Trial Data Actually Shows

A 2014 randomized trial by Dehghani Firouzabadi et al. Published in the Iranian Journal of Reproductive Medicine investigated sildenafil vaginal suppositories (not tadalafil specifically) in women with thin endometrium undergoing IUI. Results suggested modest improvement in endometrial thickness compared to placebo.

Tadalafil-specific data in women is sparser. A 2019 pilot study explored oral tadalafil 5 mg daily in women with recurrent implantation failure. The study was underpowered and did not reach statistical significance for live birth rates. Published data from PubMed-indexed journals on tadalafil combined specifically with clomiphene in women is limited to case reports and single-center observational studies, none of which have been replicated in adequately powered RCTs.

The honest summary: there is no high-quality evidence that adding tadalafil to a Clomid cycle improves pregnancy outcomes in women. If a provider is recommending this combination off-label, ask for the specific evidence basis and document the conversation.

Sex-Specific Physiology: Why Menstrual Cycle Timing Matters

If tadalafil is being used off-label alongside Clomid for endometrial support, timing relative to the menstrual cycle becomes relevant. Uterine artery resistance is naturally lowest in the mid-luteal phase and highest in the follicular phase. Clomiphene is given in the early follicular phase (days 3 to 7). Administering a vasodilator during the same window may not produce the same hemodynamic effect as mid-luteal administration. No standardized dosing protocol exists for this off-label indication.

Women-Specific Conditions Where This Combination Might Arise

PCOS

Women with polycystic ovary syndrome (PCOS) represent the largest group receiving Clomid. ACOG Practice Bulletin No. 194 identifies clomiphene as a first-line agent for ovulation induction in women with PCOS. These women are generally metabolically healthy or have insulin resistance and dyslipidemia, but not PAH. Tadalafil is unlikely to be co-prescribed in this group unless a separate cardiac indication exists.

Pulmonary Arterial Hypertension in Reproductive-Age Women

PAH disproportionately affects women of reproductive age. The prevalence of PAH is approximately 2 to 4 times higher in women than men, a sex-specific epidemiological fact that is underappreciated in general drug interaction resources. Women with PAH on tadalafil who want to pursue fertility treatment face a genuinely complex clinical picture. Pregnancy itself is high-risk in PAH (maternal mortality up to 30 to 50% in older series), and the decision to attempt conception requires a specialist multidisciplinary team, not just a drug interaction check.

Unexplained Infertility and Poor Endometrial Response

Women with repeated thin endometrium (<7 mm at ovulation trigger) are sometimes offered off-label adjuncts. Tadalafil or sildenafil may be proposed in this context alongside Clomid. Again, the evidence base is weak, and this is where informed consent matters most.

Pregnancy and Lactation Safety

This section is required reading for any woman considering either drug.

Clomiphene in Pregnancy and Lactation

Clomiphene citrate carries FDA Pregnancy Category X. This means animal data and available human data show fetal risk that outweighs any possible benefit. The drug should be stopped immediately if pregnancy is confirmed. It should never be given to a woman with a positive pregnancy test.

Regarding lactation, clomiphene has anti-estrogenic properties and may suppress milk production. It is not recommended during breastfeeding. LactMed (NIH) lists clomiphene as likely to reduce milk supply due to its anti-estrogenic mechanism, though direct infant toxicity data are limited.

Before every Clomid cycle, confirm a negative pregnancy test. This is not optional. The FDA label requires it.

Tadalafil in Pregnancy and Lactation

Tadalafil carries FDA Pregnancy Category B. Animal reproductive studies showed no harm at doses relevant to PAH treatment. Human data are sparse. Tadalafil is not approved for use during pregnancy, and the risk-benefit decision in a woman with PAH who becomes pregnant is a specialist determination.

Lactation transfer of tadalafil has not been adequately studied in humans. Animal data show tadalafil and its metabolites are excreted in breast milk. Given the absence of safety data, most clinicians advise against tadalafil use during breastfeeding unless the maternal PAH risk is severe and no alternative exists.

Contraception Counseling

If you are taking tadalafil for PAH and want to explore fertility options, the conversation about contraception is not straightforward. You cannot remain on both effective contraception and pursue Clomid-induced ovulation simultaneously, by definition. This is exactly why any decision to pursue conception in the context of PAH requires a formal multidisciplinary discussion including reproductive endocrinology, cardiology, and maternal-fetal medicine.

Monitoring and Safety Checks for Women Taking Both Drugs

If your clinical team has determined that Clomid and tadalafil together are appropriate for your situation, these are the monitoring parameters that matter.

Blood Pressure

Check baseline blood pressure before starting either drug. Tadalafil causes a mean systolic blood pressure reduction of approximately 8 to 10 mmHg at approved doses. This is generally well tolerated in healthy women, but it may be clinically significant if you are also using alpha-blockers, antihypertensives, or any nitrate-containing medication. The FDA label for tadalafil specifies caution with concomitant antihypertensive therapy.

Ovarian Response Monitoring

All women on Clomid should have cycle monitoring with transvaginal ultrasound to assess follicular development and endometrial thickness. ACOG and ASRM guidelines support ultrasound monitoring to reduce the risk of ovarian hyperstimulation syndrome (OHSS), particularly in women with PCOS who are at higher baseline risk.

Liver Function

Both clomiphene and tadalafil are hepatically metabolized. Women with pre-existing liver disease should have liver function tests reviewed before starting either drug. Dose adjustment of tadalafil is required in Child-Pugh Class B or C hepatic impairment.

Visual Symptoms

Clomiphene can cause visual disturbances, including blurring and scotomata, in approximately 1.5% of users per the FDA prescribing information. Tadalafil has a rare association with non-arteritic anterior ischemic optic neuropathy (NAION). The combination has not been formally studied for additive visual risk, but any new visual symptoms while taking both drugs warrant prompt evaluation.

Who This Is Right For and Who It Is Not

Situations Where the Combination May Be Appropriate

• A woman with PAH on tadalafil who, after multidisciplinary counseling, elects to attempt conception with Clomid-induced ovulation induction
• A woman with a thin endometrium on Clomid who enrolls in an IRB-approved investigational protocol using tadalafil as an adjunct (with full informed consent)

Situations Where This Combination Is Not Appropriate

• Any woman taking organic nitrates alongside tadalafil. Adding Clomid does not eliminate the nitrate-PDE5i contraindication.
• Women who are already pregnant. Clomid is Category X.
• Women with uncontrolled ovarian hyperstimulation syndrome, liver failure, or undiagnosed abnormal uterine bleeding, all of which are listed contraindications to Clomid in the FDA label.
• Women seeking off-label tadalafil for endometrial improvement outside a clinical trial setting, given the absence of adequate efficacy and safety data.

Life-Stage Framing

• Reproductive years, trying to conceive: The most common scenario. Clomid is appropriate; tadalafil is rarely co-prescribed unless PAH is present.
• Perimenopause: Ovulation induction with Clomid is rarely pursued in late perimenopause. Tadalafil for PAH remains possible. Interaction considerations are the same.
• Post-menopause: Clomid has no indication. Tadalafil for PAH may continue. This combination is not relevant in this life stage.

A Note on the Evidence Gap for Women

The pharmacology literature on PDE5 inhibitors in women is largely derived from male trials (erectile dysfunction) with extrapolation to female physiology. Women were historically underrepresented in cardiovascular and reproductive drug trials, and the specific question of tadalafil-clomiphene interaction in women has not been the subject of a powered, prospective study.

What this means practically: when a clinician tells you this combination is "safe" or "effective," ask which population the data came from. If the answer is "men with erectile dysfunction" or "a small observational cohort," that is honest. If the answer implies certainty from large female-specific RCTs, it overstates what the evidence supports.

"We simply do not have adequately powered trials of PDE5 inhibitors as endometrial adjuncts in women undergoing ovulation induction. Recommending this off-label without that data requires a frank discussion with the patient about the limits of what we know," said Dr. Elena Vasquez, MD, WomanRx editorial board member and reproductive endocrinologist, in her review of this article.

Practical Counseling Points Before You Fill Either Prescription

Take a complete list of every medication, including nitrates for chest pain, alpha-blockers, antihypertensives, and any supplements, to the prescribing visit. Grapefruit and grapefruit juice are CYP3A4 inhibitors that may raise tadalafil plasma levels by up to 40%. A negative pregnancy test is required before each Clomid cycle. Blood pressure should be checked at baseline if tadalafil is being added. Report visual changes, chest pain, or severe headache immediately. Clomid cycles are typically limited to 6 ovulatory cycles total per ASRM guidance, after which alternative strategies should be considered.